Publicis Touchpoint Solutions Launches T-App™: Publicis Touchpoint Solutions announces commercial availability of the industry's premier sales-force-focused decision support tool that is both cloud-based and mobile: T-App. T-App delivers anytime, anywhere, and any-data decision support where every click gets a sales representative or manager closer to a decision.
The Larvol Group, LLC announced today that it will provide a demonstration of its free innovative pharmaceutical intelligence platform, Larvol Sigma, at the 2014 Pharma Competitive Intelligence Conference and Exhibition in Parsippany, New Jersey, on September 10th.
RxMedic Systems is based in Wake Forest, NC and specializes in offering retail, hospital and independent pharmacies automated solutions for prescription filling. Shawn Judd has joined the RxMedic team as a Pharmacy Automation Specialist for the Western Region of the U.S.
This presentation will cover the scope, status and results of the surveillance inspections and what they may mean for the future of 21 CFR Part 11. At the beginning of the initiative FDA made it very clear that Part 11 is in effect and is enforced according to the original Part 11 and the Guidance from 2003.
Frederick H. Hausheer, Founder, Chairman, and Chief Executive Officer of BioNumerik, has been selected as a Professional of the Year Member of the Covington Who's Who Executive and Professional Registry. The selection recognizes Frederick H. Hausheer's commitment to excellence in Pharmaceuticals.
AdvantaPure now stocks its overbraided PTFE hose in four styles: smooth core, convoluted core, silicone-jacketed smooth core, and silicone-jacketed convoluted core. The hose offers the purity, smoothness, and non-stick properties of PTFE fluoropolymer with kink resistance and durability. Applications include fluid transfer in the pharmaceutical, food and beverage, and chemical industries.
Calvert Holdings, Inc. announced that Michael A. Recny, Ph.D., has been appointed Chief Executive Officer and has been elected a Director of the Company.
CIS announced the launch of COT Partner™ and PHS Partner™ in conjunction with the 6th Annual Government Programs (GP) Summit taking place at the Hilton Alexandria Mark Center on March 26-28.
CIS has passed a Statement on Standards for Attestation Engagements (SSAE) No. 16 audit, conducted in accordance with the American Institute of Certified Public Accountants (AICPA) standards, for its proprietary ClaimsPartner® systems and services.
AdvantaPure(R) introduces AdvantaPass, a technology developed to reduce contamination risks and ensure room isolation for critical fluid transfer. AdvantaPass applies to pharmaceutical and biopharm manufacturing where large volumes of fluid are transferred from one clean room to another. This unique system employs a wall portal through which multiple lines of Single-Use tubing can be serviced.
Calvert Research, LLC announced that the U.S. Food and Drug Administration recently accepted the Investigational New Drug application for the Phase I/II trial of ONC201, the lead experimental drug compound being developed by Oncoceutics, Inc., a Calvert Research portfolio company.
AIM Rx, is a brand-new full-service digital health care agency with a concentrated focus on complex specialty markets including oncology, immunology, virology, neurology, metabolics and orphan designated conditions.
CIS has hired Sharon H. Greeson, R.Ph as Strategic Consultant, Government Pricing and Programs to support CIS' state Medicaid service offerings and lead its "State Medicaid Initiative", which will help pharmaceutical manufacturers with their Medicaid and Medicaid Managed Care Organization (MMCO) forecasting and increase the availability of consistent data points at the state level.
The Larvol Group, LLC announced today that it will demonstrate its new KOL and Investigator tracker debuting on Larvol Sigma, a free online pharmaceutical intelligence platform, at the Pharma CI Europe conference in Barcelona on February 17th.
The American Journal of Pathology announced in a press release that a peer-reviewed scientific article about Vascular BioSciences' CAR peptide "A Novel Vascular Homing Peptide Strategy to Selectively Enhance Pulmonary Drug Efficacy in Pulmonary Arterial Hypertension" is the featured highlight article in the current February 2014 issue of The American Journal of Pathology, Volume 184, Number 2.
Vascular BioSciences announces the e-publication of "A Novel Vascular Homing Peptide Strategy to Selectively Enhance Pulmonary Drug Efficacy in Pulmonary Arterial Hypertension" to be published in the upcoming issue of the American Journal of Pathology, Volume 184, Number 2, February 2014 by Michie Toba, Abdallah Alzoubi, Kealan O'Neill, Kohtaro Abe, Takeo Urakami, Masanobu Komatsu, Diego Alvarez.
Vascular BioSciences (VBS) announced the award of a $1.2 million, milestone-based, 3-year contract from the National Heart Lung Blood Institute (NHLBI) of the National Institutes of Health (NIH) to expedite the development of CAR therapeutic peptide for pulmonary hypertension under NHLBI's Vascular Interventions/Innovations and Therapeutic Advances (VITA) program.
Satisfied Users & 
Approved Press Releases
